AstraZeneca advanced breast cancer drug fails primary endpoints

CAPItello-290 Phase III trial of Truqap/paclitaxel combo (Il Sole 24 Ore Radiocor) - London, 18 Jun - Anglo-Swedish drug company AstraZeneca said that the CAPItello-290 Phase III trial for Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer (TNBC) did not meet the dual primary endpoints of improvement in overall survival (OS) versus paclitaxel in combination with placebo in either the overall trial population or in a subgroup of patients with tumours harbouring specific biomarker alterations.

Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide. While some breast cancers may test positive for estrogen receptors, progesterone receptors, or overexpression of human epidermal growth factor receptor 2 (HER2), TNBC is defined as negative for all three.

The safety profile of Truqap in combination with paclitaxel in CAPItello-290 was broadly consistent with the known safety profile of each medicine with no new safety concerns identified. Data will be shared in due course.

Truqap is currently being evaluated in Phase III trials for the treatment of breast cancer (CAPItello-292) and prostate cancer (CAPItello-280 and CAPItello-281) in combination with established treatments.

AAA-Sch

(RADIOCOR) 18-06-24 14:57:14 (0461) 5 NNNN